Docoh
Loading...

SYBX Synlogic

News

From Benzinga Pro
Watching Agile Therapeutics, Synlogic; Traders Circulate TipRanks Article 'These 2 Penny Stocks Are Set for Massive Gains, Says Oppenheimer'
30 Nov 21
Trading Ideas
https://blog.tipranks.com/these-2-penny-stocks-are-set-for-massive-gains-says-oppenheimer/
Benzinga's Top Ratings Upgrades, Downgrades For November 24, 2021
24 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
24 Nov 21
Pre-Market Outlook, Markets, Movers
Oppenheimer Upgrades Synlogic to Outperform
24 Nov 21
News, Upgrades, Analyst Ratings
Oppenheimer analyst Mark Breidenbach upgrades Synlogic (NASDAQ:SYBX) from Perform to Outperform.
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
23 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
21 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, Top Stories, General
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
Synlogic's Return On Capital Employed Insights
11 Nov 21
Earnings
Synlogic (NASDAQ:SYBX) brought in sales totaling $916.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 10.47%, resulting in a loss of $16.05 million.
SVB Leerink Maintains Outperform on Synlogic, Lowers Price Target to $11
11 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Joseph Schwartz maintains Synlogic (NASDAQ:SYBX) with a Outperform and lowers the price target from $15 to $11.
Synlogic Q3 EPS $(0.29), Inline, Sales $916.00K Beat $140.00K Estimate
10 Nov 21
Earnings, News
Synlogic (NASDAQ:SYBX) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is a 19.44 percent increase over losses of $(0.36) per share from the same period last year. The
Earnings Scheduled For November 10, 2021
10 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Synlogic Announcesd Nature Communications Publication Highlighting Use of Synthetic Biotic Platform to Optimize Therapies for Phenylketonuria
28 Oct 21
News, Penny Stocks
Synlogic, Inc.
Synlogic Presents Data On Hyperoxaluria Program At American Society Of Nephrology Kidney Week 2021
15 Oct 21
News, FDA, Events
Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster presentations at the upcoming American Society for Nephrology
HC Wainwright & Co. Maintains Buy on Synlogic, Lowers Price Target to $7
13 Oct 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Synlogic (NASDAQ:SYBX) with a Buy and lowers the price target from $9 to $7.
Synlogic Highlights Publication Of Data Showing Novel Application Of Synthetic biotic Platform In 'Nature'
12 Oct 21
Biotech, News, FDA, General
Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the publication in Nature of preclinical research with live biotherapeutic
12 Health Care Stocks Moving In Thursday's Pre-Market Session
23 Sep 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
23 Sep 21
Biotech, News, Penny Stocks, Health Care, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
24 Stocks Moving in Thursday's Pre-Market Session
23 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Amplitude Healthcare Acquisition Corporation (NASDAQ: AMHC) rose 61.8% to $16.55 in pre-market trading. The company disclosed that shareholders approved the business combination with Jasper Therapeutics.
Synlogic Late Wednesday Priced 15M Share Public Offering of Common Stock @$3.00/Share
23 Sep 21
News, Penny Stocks, Offerings
Synlogic (NASDAQ: SYBX) announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $3.00 per share.
12 Health Care Stocks Moving In Wednesday's After-Market Session
22 Sep 21
Movers
Gainers
48 Biggest Movers From Yesterday
21 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients.

Press releases

From Benzinga Pro
Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treated with SYNB1618
22 Nov 21
Press Releases
CAMBRIDGE, Mass., Nov. 22, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of interim data
Synlogic Announces Presentation of Phenylketonuria Data at 14th International Congress of Inborn Errors of Metabolism Meeting
10 Nov 21
Press Releases
CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of new data
Synlogic Reports Third Quarter Financial Results and Provides Business Update
10 Nov 21
Earnings, Press Releases
CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the
Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria
9 Nov 21
Press Releases
CAMBRIDGE, Mass. and BOSTON, Nov. 9, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, and Ginkgo Bioworks (NYSE:DNA), the
Synlogic Announces Third Quarter 2021 Conference Call & Participation in Upcoming Banking Conference
2 Nov 21
Press Releases
CAMBRIDGE, Mass., Nov. 2, 2021 /PRNewswire/ -- Synlogic, Inc. ((
Synlogic Announces Nature Communications Publication Highlighting Use of Synthetic Biotic Platform to Optimize Therapies for Phenylketonuria
28 Oct 21
Press Releases
CAMBRIDGE, Mass., Oct. 28, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced a publication in Nature
Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021
15 Oct 21
Press Releases
CAMBRIDGE, Mass., Oct. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster presentations at
Synlogic Announces Nature Publication Demonstrating Novel Application of Synthetic Biotic Platform
12 Oct 21
Press Releases
CAMBRIDGE, Mass., Oct. 12, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the publication in
Synlogic Appoints Molly Harper as Chief Business Officer
27 Sep 21
Press Releases
CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Molly
Synlogic Announces Pricing of Public Offering of Common Stock
22 Sep 21
Offerings, Press Releases
CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (NASDAQ:SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten
Synlogic Announces Proposed Public Offering of Common Stock
22 Sep 21
Offerings, Press Releases
CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an
Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria
20 Sep 21
Press Releases
CAMBRIDGE, Mass., Sept. 20, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical
Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting
10 Sep 21
Press Releases
CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on
Synlogic Presents at Global PKU Patient Meeting
10 Sep 21
Press Releases
CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of